Recruiting

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

ClinicalTrials.gov IDNCT05851898

PhasePHASE4

Enrollment100

SponsorWake Forest University Health Sciences

Age65 Years

SexALL

I'm interested View official listing

Conditions studied

Depression in Old Age, Fragility Fracture

About this study

The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults? * Is it possible to start prescribing SNRI medication upon discharge? * What is the prevalence of depressive symptoms amongst patients with different types of injuries and weightbearing status? * What is a transition of care plan for patients who have geriatric depression and require further care? Participants will: * Undergo screening using the Geriatric Depression Scale * Start on Duloxetine 30mg daily at time of discharge * Report medication compliance and complete re-screening monthly * Complete patient reported outcome measures and 3 months, 6 months, and 1 year * Receive a referral to behavioral health, primary care, or psychiatrist for evaluation if they screen positive at any timepoint

Interventions

Drug: Duloxetine 30 mg — Duloxetine 30mg daily prescribed at discharge

Primary outcomes

Geriatric Depression Scale (Short Form) Scores (Baseline)
Geriatric Depression Scale (Short Form) Scores (up to 1 year)

Eligibility information

Inclusion Criteria: * Geriatric (greater than or equal to 65 years old) * Lower extremity fragility fractures managed operatively Exclusion Criteria: * Polytrauma * Pathological fractures * Patients on hospice * Patients with previously diagnosed psychiatric disorders * Patients with previously diagnosed dementia * Patients already taking Selective serotonin reuptake inhibitors (SSRI)s and Serotonin- norepinephrine reuptake inhibitors (SNRI)s * Patients already taking mood stabilizing medication * Unable to provide informed consent (no use of a legal authorized representative) * Patients with pre-existing life limiting diagnoses (cancer, etc.)

Study locations

Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.